A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Study sponsor: Seaport Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-03Estimated
Enrollment · participants360Estimated
Source updated2026-11-10Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.